Bend Research has announced a $20+ million expansion of its commercial spray drying capacity, including a new commercial manufacturing facility with two PSD spray dryer process trains. The company expects completion and validation of the new facility by mid-2015.
By spring of 2014, the company said that it will also have added another high-capacity PSD spray dryer process train in its existing process development pilot facility. Bend offers particle engineering and formulation development services for a variety of dosage forms, including dry powder inhalation formulations.
Bend CEO Rod Ray said, “Our new commercial wing will allow the production of registration lots, commercial launch, and continued supply of new products from the Bend Research facilities. Commercial production at Bend Research will be supported by a designed-for-purpose, risk-based quality system aligned with the principles of ICH Q10 Pharmaceutical Quality System regulations. Our quality system will incorporate best practices in late-stage development and commercial GMP production of pharmaceutical compounds.”
Since its acquisition by Capsugel in September 2013, Bend has also announced the addition of an Xcelodose micro-dosing system.
Read the Bend Research press release.
